Bioxytran Inc (BIXT)
0.117
-0.01
(-6.25%)
USD |
OTCM |
May 31, 16:00
Bioxytran Enterprise Value: 20.74M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 20.74M |
| May 30, 2024 | 22.10M |
| May 29, 2024 | 23.01M |
| May 28, 2024 | 21.19M |
| May 24, 2024 | 23.49M |
| May 23, 2024 | 23.54M |
| May 22, 2024 | 24.76M |
| May 21, 2024 | 23.98M |
| May 20, 2024 | 25.81M |
| May 17, 2024 | 22.19M |
| May 16, 2024 | 21.96M |
| May 15, 2024 | 22.84M |
| May 14, 2024 | 22.27M |
| May 13, 2024 | 20.39M |
| May 10, 2024 | 19.62M |
| May 09, 2024 | 19.51M |
| May 08, 2024 | 18.64M |
| May 07, 2024 | 19.08M |
| May 06, 2024 | 18.11M |
| May 03, 2024 | 17.95M |
| May 02, 2024 | 17.78M |
| May 01, 2024 | 18.55M |
| April 30, 2024 | 19.71M |
| April 29, 2024 | 19.44M |
| April 26, 2024 | 21.26M |
| Date | Value |
|---|---|
| April 25, 2024 | 23.89M |
| April 24, 2024 | 23.17M |
| April 23, 2024 | 25.81M |
| April 22, 2024 | 24.94M |
| April 19, 2024 | 23.45M |
| April 18, 2024 | 22.50M |
| April 17, 2024 | 21.55M |
| April 16, 2024 | 20.51M |
| April 15, 2024 | 25.50M |
| April 12, 2024 | 26.22M |
| April 11, 2024 | 25.06M |
| April 10, 2024 | 24.49M |
| April 09, 2024 | 22.76M |
| April 08, 2024 | 24.49M |
| April 05, 2024 | 24.23M |
| April 04, 2024 | 21.46M |
| April 03, 2024 | 21.01M |
| April 02, 2024 | 19.63M |
| April 01, 2024 | 19.30M |
| March 28, 2024 | 18.83M |
| March 27, 2024 | 18.03M |
| March 26, 2024 | 18.56M |
| March 25, 2024 | 19.55M |
| March 22, 2024 | 20.36M |
| March 21, 2024 | 17.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.892M
Minimum
Aug 03 2020
149.56M
Maximum
Jun 03 2019
33.06M
Average
23.74M
Median
Apr 15 2020
Enterprise Value Benchmarks
| Shuttle Pharmaceuticals Holdings Inc | 5.823M |
| NovaBay Pharmaceuticals Inc | 4.387M |
| Palatin Technologies Inc | 19.03M |
| iBio Inc | 28.91M |
| Theriva Biologics Inc | -10.98M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8003M |
| Total Expenses (Quarterly) | 0.7858M |
| EPS Diluted (Quarterly) | -0.0049 |
| Earnings Yield | -29.84% |
| Normalized Earnings Yield | -986.32 |